Mr. Daniel C. Burke was recognized as a leader in the areas of class actions and mass torts by Super Lawyers from 2013-2017. In addition, he was named as one of the National Trial Lawyers Top 100 for 2014, and one of the Nation’s Top One Percent by the National Association of Distinguished Counsel in 2015.
Mr. Burke’s practice is focused on mass tort pharmaceutical, medical device and consumer products litigation. He has actively litigated high-profile cases on behalf of thousands of injured plaintiffs in cases involving prescription drugs including Yaz/Yasmin, medical devices such as the Biomet M2a Magnum hip prosthesis and Zimmer Nexgen knee prosthesis, as well as over-the-counter consumer products including Fixodent and Poligrip denture adhesives and ReNu with MoistureLoc contact lens solution. He has supervised the day-to-day management of complex, multi-party mass tort litigation in state and federal courts and multidistrict litigation throughout the United States.
His extensive experience has been recognized by his peers and the courts, and is reflected by Mr. Burke receiving multiple appointments to leadership positions in mass tort litigations over the past ten years including: Plaintiffs’ Steering Committee in In re: Biomet M2a Magnum Hip Implant Products Liability Litigation (MDL 2391), Liaison Counsel in the New York Coordinated Plavix-Related Proceedings (Index No. 560001/12), Plaintiffs’ Steering Committee in In re: Zimmer Nexgen Knee Implant Products Liability Litigation (MDL 2272), Discovery and Law & Briefing Sub-Committees for In re: Denture Cream Products Liability Litigation (MDL 2051); and the Science and Discovery Sub-Committees for In re: Yasmin & Yaz (Drospirenone) Marketing, Sales Practices & Products Liability Litigation (MDL 2100).
Most recently, in September 2018, Mr. Burke was appointed by the U.S District Judge Karen K. Caldwell, Eastern District of Kentucky, to serve on the Plaintiffs’ Executive Committee in In re: Onglyza (Saxagliptin) and Kombiglyze (Saxagliptin and Metformin) Products Liability Litigation (MDL 2809).
Currently, Mr. Burke represents plaintiffs in a wide array of drug litigations including those involving Gadolinium-Based Contrast Agents, HIV antiviral medications (TDF), PPIs, Zofran, Fluoroquinolone Antibiotics, Testosterone Replacement Therapy, Incretins, SGLT-2 Inhibitors, Abilify, Actemra, Mirena IUD, Fosamax, Xarelto, Taxotere and Risperdal. Additionally, he is litigating matters involving medical devices including Forced Air Warming Blankets, IVC Filters, Defective Hip, Knee, Shoulder & Elbow Implants, Transvaginal and Hernia Mesh and Power Morcellators. He is also investigating consumer product claims related to various cancers caused by Cell Phone Radiation and the use of Talc.
Mr. Burke earned his bachelor’s degree in 1990 from the State University of New York at Albany (B.A., English/History), and earned his J.D. in 1993 from St. John’s University School of Law, where he was a member of St. John’s Journal of Legal Commentary.
Mr. Burke is admitted to the Bar of the State of New York. He is also admitted to practice before the United States District Courts for the Southern, Eastern and Northern Districts of New York, and he is frequently admitted pro hac vice to represent clients in various state and federal courts throughout the United States.
